UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Insulin degludec improves glycaemic control with lower nocturnal hypoglycaemia risk than insulin glargine in basal-bolus treatment with mealtime insulin aspart in Type 1 diabetes (BEGIN® Basal-Bolus Type 1): 2-year results of a randomized clinical trial

Diabetic medicine, 2013-11, Vol.30 (11), p.1293-1297

2013

Volltextzugriff (PDF)

Safety and efficacy of insulin degludec/liraglutide (IDegLira) added to sulphonylurea alone or to sulphonylurea and metformin in insulin‐naïve people with Type 2 diabetes: the DUAL IV trial

Diabetic medicine, 2017-02, Vol.34 (2), p.189-196

2017

Volltextzugriff (PDF)

One-year efficacy and safety of a fixed combination of insulin degludec and liraglutide in patients with type 2 diabetes: results of a 26-week extension to a 26-week main trial

Diabetes, obesity & metabolism, 2015-10, Vol.17 (10), p.965-973

2015

Volltextzugriff (PDF)

Continuous glucose monitoring in 2010

International journal of clinical practice (Esher), 2011-02, Vol.65 (s170), p.10-15

2011

Volltextzugriff (PDF)

Reduction in severe hypoglycemia with long-term continuous subcutaneous insulin infusion in type I diabetes

Diabetes care, 1996-04, Vol.19 (4), p.324-327

1996

Volltextzugriff (PDF)

Efficacy and safety of once-weekly glucagon-like peptide 1 receptor agonist albiglutide (HARMONY 1 trial): 52-week primary endpoint results from a randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes mellitus not controlled on pioglitazone, with or without metformin

Diabetes, obesity & metabolism, 2014-12, Vol.16 (12), p.1257-1264

2014

Volltextzugriff (PDF)

Mealtime fast‐acting insulin aspart versus insulin aspart for controlling postprandial hyperglycaemia in people with insulin‐resistant Type 2 diabetes

Diabetic medicine, 2019-06, Vol.36 (6), p.771-775

2019

Volltextzugriff (PDF)

Insulin degludec improves glycaemic control with lower nocturnal hypoglycaemia risk than insulin glargine in basal-bolus treatment with mealtime insulin aspart in Type 1 diabetes (BEGIN(®) Basal-Bolus Type 1): 2-year results of a randomized clinical trial

Diabetic medicine, 2013-11, Vol.30 (11), p.1293

2013

Volltextzugriff (PDF)

Continuous glucose monitoring used to adjust diabetes therapy improves glycosylated hemoglobin: a pilot study

Diabetes Research and Clinical Practice, 1999-12, Vol.46 (3), p.183-190

1999

Volltextzugriff (PDF)

Patient-reported outcomes following treatment with the human GLP-1 analogue liraglutide or glimepiride in monotherapy: results from a randomized controlled trial in patients with type 2 diabetes

Diabetes, obesity & metabolism, 2010-07, Vol.12 (7), p.604-612

2010

Volltextzugriff (PDF)

Continuous glucose monitoring

International journal of clinical practice. Supplement, 2010-02 (166), p.11

2010

Volltextzugriff (PDF)

Performance evaluation of the MiniMed continuous glucose monitoring system during patient home use

Diabetes technology & therapeutics, 2000, Vol.2 (1), p.49-56

2000

Volltextzugriff (PDF)

Continuous glucose monitoring

International journal of clinical practice (Esher), 2010-02, Vol.64 (s166), p.11-15

2010

Volltextzugriff (PDF)

Efficacy, Safety, and Pump Compatibility of Insulin Aspart Used in Continuous Subcutaneous Insulin Infusion Therapy in Patients With Type 1 Diabetes

Diabetes care, 2001-01, Vol.24 (1), p.69-72

2001

Volltextzugriff (PDF)

L’insuline asparte ultra-rapide vs insuline asparte en Basal-Bolus améliore la glycémie postprandiale chez des patients DT2 incontrôlés dans une étude en double-aveugle : étude onset® 2

Annales d'endocrinologie, 2016-09, Vol.77 (4), p.323-324

2016

Volltextzugriff (PDF)

Continuous Glucose Monitoring and Intensive Treatment of Type 1 Diabetes

The New England journal of medicine, 2008-10, Vol.359 (14), p.1464-1476

2008

Volltextzugriff (PDF)

Self-monitoring of blood glucose

International journal of clinical practice (Esher), 2010-02, Vol.64 (s166), p.1-10

2010

Volltextzugriff (PDF)

Clinical utility of the continuous glucose monitoring system

Diabetes technology & therapeutics, 2000, Vol.2 Suppl 1 (supplement 1), p.S35-41

Bode, B W

2000

Volltextzugriff (PDF)

What's ahead in glucose monitoring?: New techniques hold promise for improved ease and accuracy

Postgraduate medicine, 2001-04, Vol.109 (4), p.41-49

2001

Volltextzugriff (PDF)

Continuous glucose monitoring in 2010: Sensors

International journal of clinical practice (Esher), 2011-02, Vol.65, p.10-15

2011

Volltextzugriff (PDF)

Using the continuous glucose monitoring system to improve the management of type 1 diabetes

Diabetes technology & therapeutics, 2000, Vol.2 Suppl 1 (supplement 1), p.S43-48

2000

Volltextzugriff (PDF)

Glucommander: A computer-directed intravenous insulin system shown to be safe, simple, and effective in 120,618 h of operation

Diabetes care, 2005-10, Vol.28 (10), p.2418-2423

2005

Volltextzugriff (PDF)

Continuous Subcutaneous Insulin Infusion (CSII) of Insulin Aspart Versus Multiple Daily Injection of Insulin Aspart/Insulin Glargine in Type 1 Diabetic Patients Previously Treated With CSII

Diabetes care, 2005-03, Vol.28 (3), p.533-538

2005

Volltextzugriff (PDF)

Continuous subcutaneous Insulin infusion and multiple daily injection therapy are equally effective in type 2 diabetes: A randomized, parallel-group, 24-week study

Diabetes care, 2003-09, Vol.26 (9), p.2598-2603

2003

Volltextzugriff (PDF)

Efficacy of Inhaled Insulin in Patients With Type 2 Diabetes not Controlled With Diet and Exercise: A 12-week, randomized, comparative trial

Diabetes care, 2005-08, Vol.28 (8), p.1922-1928

2005

Volltextzugriff (PDF)

1 – 25 von 797

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(723)
Mit Volltextzugriff
(673)

Publikationsform

2 weitere anzeigen...

Weniger anzeigen...

Sprache

1 weiteren anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(2)
... seit 90 Tagen
(8)

Menü

Weitere Dienste

Einstellungen

Insulin degludec improves glycaemic control with lower nocturnal hypoglycaemia risk than insulin glargine in basal-bolus treatment with mealtime insulin aspart in Type 1 diabetes (BEGIN® Basal-Bolus Type 1): 2-year results of a randomized clinical trial

Safety and efficacy of insulin degludec/liraglutide (IDegLira) added to sulphonylurea alone or to sulphonylurea and metformin in insulin‐naïve people with Type 2 diabetes: the DUAL IV trial

One-year efficacy and safety of a fixed combination of insulin degludec and liraglutide in patients with type 2 diabetes: results of a 26-week extension to a 26-week main trial

Continuous glucose monitoring in 2010

Reduction in severe hypoglycemia with long-term continuous subcutaneous insulin infusion in type I diabetes

Efficacy and safety of once-weekly glucagon-like peptide 1 receptor agonist albiglutide (HARMONY 1 trial): 52-week primary endpoint results from a randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes mellitus not controlled on pioglitazone, with or without metformin

Mealtime fast‐acting insulin aspart versus insulin aspart for controlling postprandial hyperglycaemia in people with insulin‐resistant Type 2 diabetes

Insulin degludec improves glycaemic control with lower nocturnal hypoglycaemia risk than insulin glargine in basal-bolus treatment with mealtime insulin aspart in Type 1 diabetes (BEGIN(®) Basal-Bolus Type 1): 2-year results of a randomized clinical trial

Continuous glucose monitoring used to adjust diabetes therapy improves glycosylated hemoglobin: a pilot study

Patient-reported outcomes following treatment with the human GLP-1 analogue liraglutide or glimepiride in monotherapy: results from a randomized controlled trial in patients with type 2 diabetes

Continuous glucose monitoring

Performance evaluation of the MiniMed continuous glucose monitoring system during patient home use

Continuous glucose monitoring

Efficacy, Safety, and Pump Compatibility of Insulin Aspart Used in Continuous Subcutaneous Insulin Infusion Therapy in Patients With Type 1 Diabetes

L’insuline asparte ultra-rapide vs insuline asparte en Basal-Bolus améliore la glycémie postprandiale chez des patients DT2 incontrôlés dans une étude en double-aveugle : étude onset® 2

Continuous Glucose Monitoring and Intensive Treatment of Type 1 Diabetes

Self-monitoring of blood glucose

Clinical utility of the continuous glucose monitoring system

What's ahead in glucose monitoring?: New techniques hold promise for improved ease and accuracy

Continuous glucose monitoring in 2010: Sensors

Using the continuous glucose monitoring system to improve the management of type 1 diabetes

Glucommander: A computer-directed intravenous insulin system shown to be safe, simple, and effective in 120,618 h of operation

Continuous Subcutaneous Insulin Infusion (CSII) of Insulin Aspart Versus Multiple Daily Injection of Insulin Aspart/Insulin Glargine in Type 1 Diabetic Patients Previously Treated With CSII

Continuous subcutaneous Insulin infusion and multiple daily injection therapy are equally effective in type 2 diabetes: A randomized, parallel-group, 24-week study

Efficacy of Inhaled Insulin in Patients With Type 2 Diabetes not Controlled With Diet and Exercise: A 12-week, randomized, comparative trial

Suchergebnisse filtern